Baseline characteristics of the 60 immune thrombocytopenic purpura patients
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Mean | 48 |
| Range | 18-84 |
| Female sex, no. (%) | 40 (67) |
| Years since diagnosis | |
| Median | 1.9 |
| IQR | 0.9; 5.2 |
| Platelet count nadir within 15 days of inclusion, ×109/L | |
| Median | 14.0 |
| IQR | 7.0; 19.5 |
| Bleeding score at inclusion | |
| Median | 1.5 |
| IQR | 0; 4 |
| Previous therapy | |
| Median no. of therapies | 2 |
| IQR | 2; 3.5 |
| Previously took corticosteroids, no. (%) | 57 (95) |
| Response to corticosteroids, n/N (%) | 49/57 (86) |
| Previously received IVIgs, no. (%) | 35 (58) |
| Response to IVIgs, n/N (%) | 30/35 (86) |
| Corticosteroids at inclusion, no. (%) | 21 (35) |
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Mean | 48 |
| Range | 18-84 |
| Female sex, no. (%) | 40 (67) |
| Years since diagnosis | |
| Median | 1.9 |
| IQR | 0.9; 5.2 |
| Platelet count nadir within 15 days of inclusion, ×109/L | |
| Median | 14.0 |
| IQR | 7.0; 19.5 |
| Bleeding score at inclusion | |
| Median | 1.5 |
| IQR | 0; 4 |
| Previous therapy | |
| Median no. of therapies | 2 |
| IQR | 2; 3.5 |
| Previously took corticosteroids, no. (%) | 57 (95) |
| Response to corticosteroids, n/N (%) | 49/57 (86) |
| Previously received IVIgs, no. (%) | 35 (58) |
| Response to IVIgs, n/N (%) | 30/35 (86) |
| Corticosteroids at inclusion, no. (%) | 21 (35) |
IQR indicates interquartile range, expressed as the 1st; 3rd quartiles; IVIgs, intravenous immunoglobulins.